First Quarter Financial Report 2019

09. May 2019 | 2 min read

Moss, 9.5.2019

 

Gentian Diagnostics AS announces its results for the first quarter of 2019. The highlights include:

  • Good start to the new fiscal year with sales revenues of MNOK 10.6 for the quarter.
  • Record sales achieved for fCAL®turbo, our innovative biomarker for the diagnosis of inflammatory bowel disease.
  • New scientific study results confirm GCAL as a promising biomarker for the diagnosis of bacterial infections.

 

Please find the report and results presentation enclosed. The documents is also available on Oslo Børs.

 

Q1 2019 GD Interim presentation

Q1 2019 GD Interim report

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525

MeldingsID: 476431
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL

 

You may also read


Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..